Personalized Management of Chronic Pain

A powerful case study in how personalized medication management program can help significantly improve patient quality.

Given that the patient was a CYP2C9 intermediate metabolizer, he had approximately one-half the normal enzyme activity; he would require less than standard dosages to prevent overdose toxicities and drug interactions, as well as to provide optimal therapeutic response to CYP2C9-inactivated medications. In addition, the report described the patient as being highly sensitive to warfarin according to his VKORC1 enzyme profile.

Read more at this link: Personalized Management of Chronic Pain